VCM
DNLI icon

Versant Capital Management’s Denali Therapeutics DNLI Stock Holding History

Versant Capital Management’s Portfolio DNLI Stock Details DNLI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$42K Buy
1,633
+157
+11% +$3.23K ﹤0.01% 1492
2026
Q1 		$28.3K Hold
1,476
– – ﹤0.01% 1611
2025
Q4 		$24.4K Hold
1,476
– – ﹤0.01% 1520
2025
Q3 		$21.4K Buy
1,476
+190
+15% +$2.73K ﹤0.01% 1541
2025
Q2 		$18K Buy
1,286
+570
+80% +$8.02K ﹤0.01% 1590
2025
Q1 		$9.73K Buy
716
+513
+253% +$9.83K ﹤0.01% 1739
2024
Q4 		$4.14K Hold
203
– – ﹤0.01% 1848
2024
Q3 		$5.91K Buy
203
+102
+101% +$2.53K ﹤0.01% 1242
2024
Q2 		$2.35K Sell
101
-8
-7% -$154 ﹤0.01% 1460
2024
Q1 		$2.24K Buy
109
+101
+1,263% +$1.9K ﹤0.01% 1313
2023
Q4 		$172 Buy
+8
New +$158 ﹤0.01% 1880
2023
Q3 		– Sell
-18
Closed -$531 – 1966
2023
Q2 		$531 Buy
+18
New +$506 ﹤0.01% 1820
2019
Q4 		– Sell
-39
Closed – – 1397
2019
Q3 		$0 Buy
+39
New +$745 ﹤0.01% 1408

Other funds holding DNLI

T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Temasek Holdings
Temasek Holdings Singapore $37.3B AUM 12.6% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Versant Capital Management's DNLI Position: Q2 2026 in Review

Versant Capital Management increased its Denali Therapeutics (DNLI) stake by 11% in Q2 2026, buying an estimated $3.23K and bringing the position to 1,633 shares worth $42K. The position accounts for ﹤0.01% of the portfolio, ranked #1492.

Versant Capital Management first reported a position in DNLI in Q3 2019 and has held it in 13 quarters since. 292 funds tracked by Wall St. Rank hold DNLI as of Q2 2026.

  • Versant Capital Management held 1,633 shares of Denali Therapeutics worth $42K as of Q2 2026.
  • Versant Capital Management bought 157 Denali Therapeutics shares in Q2 2026, an estimated $3.23K.
  • Denali Therapeutics made up ﹤0.01% of Versant Capital Management's portfolio in Q2 2026, its #1492 holding.
  • Versant Capital Management first reported a position in Denali Therapeutics in Q3 2019 and has held it in 13 quarters since.
  • 292 funds tracked by Wall St. Rank held Denali Therapeutics as of Q2 2026.

Based on Versant Capital Management's 13F filing for Q2 2026, filed 2 Jul 2026.